Does Rallies show Form 4 insider transactions for RCEL?

Yes. Rallies tracks RCEL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RCEL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RCEL. It does not provide personalized investment advice.

RCEL (Avita Medical, Inc. Common Stock) Stock Analysis - Insider Trades

Avita Medical, Inc. Common Stock (RCEL) is a publicly traded Healthcare sector company. As of May 21, 2026, RCEL trades at $4.32 with a market cap of $128.95M and a P/E ratio of -2.74. RCEL moved +3.22% today. Year to date, RCEL is +24.50%; over the trailing twelve months it is -35.52%. Its 52-week range spans $3.22 to $14.16. Analyst consensus is strong buy with an average price target of $7.17. Rallies surfaces RCEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RCEL stock inside the company?

Recent RCEL insider activity includes O'Toole David D bought 1.80K, O'Toole David D bought 3.00K, McNamara Robert bought 10.00K, O'Toole David D bought 2.00K, and McNamara Robert bought 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RCEL Key Metrics

Key financial metrics for RCEL
Metric	Value
Price	$4.32
Market Cap	$128.95M
P/E Ratio	-2.74
EPS	$-1.56
Dividend Yield	0.00%
52-Week High	$14.16
52-Week Low	$3.22
Volume	0
Avg Volume	0
Revenue (TTM)	$72.35M
Net Income	$-45.34M
Gross Margin	81.36%

Recent RCEL Insider Trades

O'Toole David D bought 1.80K (~$8.60K) on Mar 11, 2026.
O'Toole David D bought 3.00K (~$12.45K) on Feb 19, 2026.
McNamara Robert bought 10.00K (~$45.00K) on Aug 28, 2025.
O'Toole David D bought 2.00K (~$9.04K) on Aug 26, 2025.
McNamara Robert bought 10.00K (~$50.00K) on Aug 19, 2025.

Latest RCEL News

Avita Medical Q1 revenue rises 4% to $19.3M, inks $25.5M BARDA deal — May 14, 2026
AVITA Medical Gains TGA Approval and NZ Listing for RECELL GO System — Apr 29, 2026
Avita Medical Shares Rally 14.1% as Founder Wins ABA Lifetime Achievement Award — Apr 15, 2026
AVITA Medical’s Cohealyx Cuts Mean Graft Time by Nearly 20 Days — Apr 14, 2026
AVITA Medical Secures $25.5M BARDA Deal for 3,000 RECELL Units — Apr 8, 2026

RCEL Analyst Consensus

4 analysts cover RCEL: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.17.

Common questions about RCEL

Who is trading RCEL stock inside the company?: Recent RCEL insider activity includes O'Toole David D bought 1.80K, O'Toole David D bought 3.00K, McNamara Robert bought 10.00K, O'Toole David D bought 2.00K, and McNamara Robert bought 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RCEL?: Yes. Rallies tracks RCEL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RCEL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RCEL. It does not provide personalized investment advice.